{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e8308ce6b0fef1a38c4a215/6a1065c7163f100183363ffa?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Menin inhibitors in AML: Where are we now, and where are we going? ","description":"<p>During a meeting of the AML Hub Steering Committee, held on February 19, 2026, Jorge Cortes chaired a discussion on the topic, Menin inhibitors in AML: Where are we now, and where are we going? The discussion featured contributions from Charles Craddock, Brian Huntly, and Jeffrey Lancet. </p><p><br></p><p>This educational resource is independently supported by Johnson &amp; Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.</p>","author_name":"Scientific Education Support"}